Home » Newsletters » BioWorld

BioWorld

Nov. 4, 1993

View Archived Issues

CORTEX DEVELOPING MEMORY ENHANCER

ENSYS RAISES $18M IN IPO

ISIS FILES IND ON ANTISENSE DRUG FOR CMV RETINITIS

NEOZYME TO DISTRIBUTE $49M TO SHAREHOLDERS

REGENERON CO-DEVELOPING NEW NEURO-MOLECULE

PENEDERM RAISES $22M IN IPO

BIOJECT RAISES $11.75M IN OFFERING

SOMATIX, BAXTER FORM GENE THERAPY PARTNERSHIP

NEW PROSPECT OF DIABETES THERAPY AND PREVENTION

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...